{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:18:25Z","timestamp":1760833105548,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bmcl.2019.03.026","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T01:36:42Z","timestamp":1553132202000},"page":"1168-1172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model"],"prefix":"10.1016","volume":"29","author":[{"given":"Woo Seung","family":"Son","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-Sung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0419-8950","authenticated-orcid":false,"given":"Ae Nim","family":"Pae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10 Suppl","key":"10.1016\/j.bmcl.2019.03.026_b0005","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","article-title":"Treatment of neuropathic pain: an overview of recent guidelines","volume":"122","author":"O'Connor","year":"2009","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.bmcl.2019.03.026_b0010","first-page":"210","article-title":"Drug therapy of neuropathic pain: current developments and future perspectives","volume":"15","author":"Muthuraman","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"8","key":"10.1016\/j.bmcl.2019.03.026_b0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.bmcl.2019.03.026_b0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.bmcl.2019.03.026_b0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.bmcl.2019.03.026_b0030","series-title":"Seminars in neurology","first-page":"425","article-title":"Treatment of neuropathic pain","author":"Jefferies","year":"2010"},{"issue":"6","key":"10.1016\/j.bmcl.2019.03.026_b0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/187152706779025490","article-title":"The role of T-type calcium channels in peripheral and central pain processing","volume":"5","author":"Todorovic","year":"2006","journal-title":"CNS Neurol Disord Drug Targets."},{"issue":"4","key":"10.1016\/j.bmcl.2019.03.026_b0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ddr.20103","article-title":"T-type calcium channels: an emerging therapeutic target for the treatment of pain","volume":"67","author":"Snutch","year":"2006","journal-title":"Drug Develop Res."},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.026_b0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1152\/physrev.00018.2002","article-title":"Molecular physiology of low-voltage-activated t-type calcium channels","volume":"83","author":"Perez-Reyes","year":"2003","journal-title":"Physiol Rev."},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.026_b0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tips.2008.10.004","article-title":"Regulation of neuronal T-type calcium channels","volume":"30","author":"Iftinca","year":"2009","journal-title":"Trends Pharmacol Sci."},{"issue":"6670","key":"10.1016\/j.bmcl.2019.03.026_b0055","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/36110","article-title":"Molecular characterization of a neuronal low-voltage-activated T-type calcium channel","volume":"391","author":"Perez-Reyes","year":"1998","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.026_b0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/01.RES.83.1.103","article-title":"Cloning and characterization of \u03b11H from human heart, a member of the T-type Ca2+ channel gene family","volume":"83","author":"Cribbs","year":"1998","journal-title":"Circ Res."},{"issue":"6","key":"10.1016\/j.bmcl.2019.03.026_b0065","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1523\/JNEUROSCI.19-06-01912.1999","article-title":"Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family","volume":"19","author":"Lee","year":"1999","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.bmcl.2019.03.026_b0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1016-8478(23)17576-5","article-title":"Attenuated neuropathic pain in Cav3.1 null mice","volume":"25","author":"Na","year":"2008","journal-title":"Mol Cells"},{"issue":"1\u20132","key":"10.1016\/j.bmcl.2019.03.026_b0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pain.2009.06.012","article-title":"In vivo silencing of the CaV3. 2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy","volume":"145","author":"Messinger","year":"2009","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.bmcl.2019.03.026_b0080","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/mol.60.5.1121","article-title":"Block of cloned human T-type calcium channels by succinimide antiepileptic drugs","volume":"60","author":"Gomora","year":"2001","journal-title":"Mol Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.bmcl.2019.03.026_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2005.08.017","article-title":"The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil","volume":"521","author":"Barton","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.026_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(99)00153-7","article-title":"Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels","volume":"39","author":"Jimenez","year":"2000","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.bmcl.2019.03.026_b0095","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1124\/mol.66.6.1652","article-title":"State-dependent mibefradil block of Na+ channels","volume":"66","author":"McNulty","year":"2004","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.026_b0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1085\/jgp.200609665","article-title":"Pharmacological dissection and distribution of NaN\/Nav1.9, T-type Ca2+ currents, and mechanically activated cation currents in different populations of DRG neurons","volume":"129","author":"Coste","year":"2007","journal-title":"J Gen Physiol"},{"issue":"9","key":"10.1016\/j.bmcl.2019.03.026_b0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/01.CIR.98.9.831","article-title":"Withdrawal of Posicor from market","volume":"98","author":"SoRelle","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bmcl.2019.03.026_b0110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bcp.2014.03.015","article-title":"A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats","volume":"89","author":"Jarvis","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.bmcl.2019.03.026_b0115","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1124\/mol.111.073205","article-title":"TTA-P2 Is a Potent and Selective Blocker of T-Type Calcium Channels in Rat Sensory Neurons and a Novel Antinociceptive Agent","volume":"80","author":"Choe","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.026_b0120","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1080\/14756366.2018.1513926","article-title":"Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain","volume":"33","author":"Yang","year":"2018","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2019.03.026_b0125","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bmc.2004.01.034","article-title":"First pharmacophoric hypothesis for T-type calcium channel blockers","volume":"12","author":"Doddareddy","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.03.026_b0130","article-title":"Compound based on 5-(substituted alkyl-aminomethyl) isoxazole acting as a t-type calcium channel antagonist","author":"Choo","year":"2012","journal-title":"WO2012\/115446"},{"issue":"1","key":"10.1016\/j.bmcl.2019.03.026_b0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbrc.2004.09.069","article-title":"The biochemical activation of T-type Ca2+ channels in HEK293 cells stably expressing \u03b11G and Kir2. 1 subunits","volume":"324","author":"Kim","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"7083","key":"10.1016\/j.bmcl.2019.03.026_b0140","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bmcl.2019.03.026_b0145","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1016\/j.bmcl.2011.07.087","article-title":"Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers","volume":"21","author":"Woo","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.bmcl.2019.03.026_b0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0304-3959(92)90041-9","article-title":"An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat","volume":"50","author":"Kim","year":"1992","journal-title":"Pain"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19301659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19301659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:27:47Z","timestamp":1760772467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19301659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0960894X19301659"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.03.026","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}